[Use of recombinant erythropoietin in surgery--are the costs justified?].
The combination of autologous blood donation and rHuEPO therapy is rarely justified for medical and economic reasons. Adequate alternative indications for the use of rHuEPO perioperatively have yet to be studied. Therefore, in addition to the increasing costs of safe homologous blood products and the decreasing costs of recombinant proteins, a reevaluation of the cost-effectivity relationship will be mandatory for rHuEPO in surgery.
Wolff
M
M
Klinik und Poliklinik für Chirurgie, Rheinische Friedrich-Wilhelms-Universität Bonn.
Fandrey
J
J
Jelkmann
W
W
Hirner
A
A
D001804:Blood Transfusion, Autologous / Q000191:economics*; D003362:Cost-Benefit Analysis; D017707:Erythrocyte Transfusion / Q000191:economics; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin
Einsatz von rekombinantem Erythropoietin in der Chirurgie--Sind die Kosten gerechtfertigt?